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Engineering proteins to bind small molecules presents a challenge as daunting as
drug discovery, for both hinge upon our understanding of receptor^ligand
molecular recognition. However, powerful techniques from combinatorial
molecular biology can be used to rapidly select arti¢cial receptors. While
traditionally researchers have relied upon antibody technologies as a source of
new binding proteins, the lipocalin scaffold has recently emerged as an adaptable
receptor for small molecule binding. `Anticalins', engineered lipocalin variants,
offer some advantages over traditional antibody technology and illuminate
features of molecular recognition between receptors and small molecule ligands.
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Introduction
The challenge of discovering small molecule ligands for
protein receptors is well appreciated by, among others,
the pharmaceutical industry, which spent the majority of
its $24 billion pharmaceutical research and development
budget in 1999 on small molecule drug discovery [1].
The crux of the drug discovery challenge is the currently
inadequate understanding of the forces governing molec-
ular recognition. Molecular recognition is also central to
essentially all processes in biology. Thus, the study of mo-
lecular recognition is a problem of great practical and the-
oretical importance.
An interesting approach to explore molecular recognition
inverts the drug discovery problem, start with a known
small molecule and search for a ‘receptor’ capable of spe-
ci¢cally binding the small molecule. While this approach is
certainly not a new one, a milestone has recently been
achieved in establishing a new class of proteins as user-
friendly small molecule binding agents. Using in vitro li-
gand binding selection from a protein library, researchers in
the Skerra laboratory have engineered speci¢c tight bind-
ing proteins to several small molecules (Figure 1) [2,3].
These workers have departed from the traditional antibody
scaffold as a source of novel binding proteins, using a
member of the lipocalin family as a template to create
novel proteins dubbed ‘anticalins’ [2,3].
Though many techniques for producing libraries of pro-
teins are available, the studies reviewed here make use
of randomly mutated proteins displayed on the surface of
¢lamentous bacteriophage, viruses capable of infecting
only bacteria (reviewed in [4]). Diversity can be targeted
to particular regions of a displayed protein through stan-
dard molecular biology techniques [5], or can be distrib-
uted throughout a displayed protein [6]. The phage display
technique allows for in vitro binding selection, a simple
and rapid process, followed by multiple rounds of growth
in an Escherichia coli host to amplify the most ¢t binding
variants and further selection. This process, often de-
scribed as in vitro evolution, can be readily adapted to
many different small molecules for the evolution of novel
binding activities of proteins. Using a combination phage-
and-plasmid (phagemid) system, monovalent phage display
of proteins allows for stringent binding selections that dis-
criminate between high af¢nity and low af¢nity binding
interactions [5].
In addition to the antibody and anticalin scaffolds, other
protein scaffolds have been modi¢ed to create libraries of
binding proteins (reviewed in [7]). The cytochrome b562
scaffold has been adapted to bind N-methyl-p-nitrobenzyl-
amine conjugated to bovine serum albumin (BSA) [8].
Generally, these binding protein libraries have successfully
bound new protein ligands, but not small molecule ligands
(reviewed in [7]). For example, the cytochrome b562 scaf-
fold fails to bind unconjugated N-methyl-p-nitrobenzyl-
amine. The engineered lipocalin libraries are distinct
from previously described arti¢cial receptor libraries, be-
cause the resulting anticalins bind a variety of structurally
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unrelated small molecules that are not covalently linked to
proteins.
Lipocalins from butter£ies and pigs
Among the many homologous protein families inherited
through evolution from insects to mammals, lipocalins are
perhaps uniquely suited for diverse tasks in small molecule
binding (reviewed in [9]). The lipocalins are a family of
‘professional binding proteins’ that specialize in binding
hydrophobic small molecules, such as biliverdin IXQ , a
butter£y chromophore; retinal, an important pigment for
visualization; or pheromones, for which binding proteins
are known in pigs. The structures of several lipocalins
bound to their respective ligands have been reported (re-
viewed in [10] and also [9]).
Various members of the family feature deep to relatively
shallow binding sites that are formed by the central core of
a L-barrel and protruding loops (see Figure 2). This is
clearly seen in the structure of a complex between the
butter£y-derived bilin binding protein (BBP) and the nat-
ural chromophore biliverdin IXQ (Figure 2) [11]. From the
crystal structure, BBP is a tetrameric lipocalin, with one
ligand bound per monomer. The ligand binding site is
quite deep (Figure 2) and largely nonpolar, although two
residues, Glu(38) and Tyr(94) of BBP, form H-bonds with
biliverdin and two ligand-bound water molecules [11]. Fur-
thermore, the side chain of Tyr(94) forms a cap blocking
free diffusion of biliverdin from the binding site, yet leav-
ing the carboxylate oxygens of biliverdin accessible to
water. By analogy with the ligand binding loops of anti-
bodies, the BBP loop structure presents a logical starting
point for the generation of diversity using site-directed
mutagenesis. Many different amino acid sequences may
be accommodated in such surface loops without global
disruption of the scaffold structure. Accordingly, Skerra et
al. began their studies by mutating 16 loop residues within
a monomeric variant of BBP (see Table 1).
Anticalins: lipocalins with engineered ligand
speci¢city
The phage library of BBP variants was created by fusion of
the BBP variant to a phagemid-encoded protein, g3p,
which is expressed in the E. coli host and incorporated
into the virion coat of M13 bacteriophage. Fluorescein
was chosen as an initial small molecule ligand, an appro-
priate choice, since binding af¢nity is readily measured by
spectrophotometric assays, and anti-£uorescein antibodies,
useful for structural and af¢nity comparison, have been
previously described. As in the case of antibody-phage
libraries [12], ligand-speci¢c binding BBP variants were
obtained by screening the phage-displayed anticalin library
Figure 1. Small molecule ligands for
antibodies, lipocalins and/or anticalins.
Shown are £uorescein, rhodamine (110),
biliverdin IXQ , axerophthene, digoxin,
digoxigenin, digitoxigenin, and ouabain
structures.
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for binding to BSA-conjugated or RNaseA-conjugated £u-
orescein. One such anticalin variant, FluA (see Table 1),
was identi¢ed and found to have 35 nM af¢nity (Kd) for
£uorescein. Remarkably, the ligand speci¢city was high,
with Kds 100 WM for the £uorescein analog rhodamine
(see Figure 1).
The BBP structure also provided the basis for a structural
model of the £uorescein^FluA anticalin binding interac-
tion. Having noted that basic side chain substitutions oc-
curred in FluA at several randomized sites, Beste et al. [2]
demonstrated the importance of two of these side chains.
Substitution of Arg(58) with Lys or His(127) with Phe
caused losses in £uorescein binding af¢nity of 59-fold
and 13-fold, respectively. Since these residues are impor-
tant for ligand binding, placement of the modeled £uores-
cein in the binding site described for BBP was made by
analogy with the His (VL 27d) and Arg (VH 34) residues of
the anti-£uorescein antibody 4-4-20 described below.
While this is a tentative model, this placement of the £uo-
rescein molecule within the loop-de¢ned ligand binding
site seems plausible.
More recently, Schlehuber et al. [3] reported on steroid
binding anticalins. After phage binding selections and col-
ony screening a 16-site randomized BBP-phage library for
binding to a digoxigenin-conjugated RNaseA, a selectant
was identi¢ed with moderate af¢nity (KdW300 nM) to
digoxigenin. This variant, called DigA, was af¢nity-matured
using additional phage display libraries which were
randomized at four of the originally mutated positions (res-
idues 34^37), as well as two additional positions (Table 1)
involved in an ion pair within BBP. Again, binding selec-
tions and colony screening were used to identify optimized
Figure 2. Ribbon diagrams of two arti¢cial receptor scaffolds. (A) The lipocalin domain (Protein Database entry 1BBP) of BBP bound to
the butter£y chromophore biliverdin IXQ (depicted with cpk model). One subunit of the lipocalin tetramer is shown, as Beste et al. [2] used
a monomeric BBP mutant. (B) Fluorescein (cpk) bound to the light (VL) and heavy (VH) chains of the anti-£uorescein Fab 4-4-20 (1FLR).
The ¢gure was prepared using Molscript-II [27] and RASTER-3D [28].
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variants. Ultimately, a variant called DigA16 was obtained,
which bound the ligand with 30 nM af¢nity, but had no
detectable binding to the related compound ouabain (see
Figure 1). Another analog of the target ligand, digitoxige-
nin, happened to bind even more tightly to this anticalin,
with a Kd of 2 nM.
For the DigA16 anticalin, the authors suggest that the
steroid is well buried in the anticalin L-barrel. Such a var-
iation on the lipocalin:small molecule binding theme has
been observed in the binding of a retinol analog in the
structure of the axerophthene:lipocalin (bovine retinol
binding protein) complex [13,30]. This axerophthene struc-
ture reveals a lipocalin binding site that extends well into
the interior of the L-barrel, though the exposed loops are
also involved in binding. The degree to which axeroph-
thene is buried by the protein is especially striking (Figure
3D). Thus, the L-barrel region of lipocalins provides addi-
tional possibilities for ligand interactions.
The recent successes of anticalin engineering suggest that
many different small molecules could be recognized with
high speci¢city by selected members of a lipocalin library,
diversi¢ed at only 16 residues. The precise interactions
involved in anticalin recognition await structural studies
on ligand-bound anticalin complexes.
Antibodies with small molecule binding
speci¢city
For comparison with the new anticalin scaffold, the exten-
sive record of antibodies is instructive, as antibodies have
proven useful as binding proteins for small molecules.
Anti-digitoxigenin, anti-nitrophenol, anti-biotin and anti-
£uorescein antibodies are workhorses in biochemistry, as
speci¢c binders to covalently modi¢ed proteins. Often,
these antibodies can bind both the protein-conjugated
and the unconjugated small molecule; for example,
the structure of an anti-£uorescein antibody bound to
free, unconjugated £uorescein has been solved [14]. Anti-
bodies capable of binding small molecules that are
meant to mimic the transition states of reactions have
been used to explore the role of molecular recognition
in reaction catalysis (reviewed in [15]). In addition, the
large number of three-dimensional structures of antibodies
bound to small molecule ligands illustrates different
strategies for one scaffold binding to a variety of mole-
cules.
Fluorescein (Figure 1), long used as a £uorescent molec-
ular probe, was an early target for the generation of anti-
bodies using traditional hybridoma as well as antibody-
phage technology [12]. Anti-£uorescein antibodies with
binding af¢nities (Kd) in the range of 100 pM to 10 WM
have been reported (reviewed in [16]). The high resolution
X-ray structure [14] of one £uorescein binding antibody,
known as 4-4-20 Fab, provides a glimpse of how effec-
tively a monoclonal antibody can bind a small molecule
(see Figure 3A). Antibodies bind to their antigens through
various combinations of contacts made from among six
hypervariable complementarity determining regions
(CDRs). Five of the six hypervariable CDRs are used by
4-4-20 Fab to construct a binding site for £uorescein. The
binding site is a deep cleft, burying 92% of the surface-
accessible area of £uorescein. The cleft is formed between
Table 1
Designing anticalin-phage libraries. Each sequence begins with the residue numbered to the left of the sequence.
BBP 1 NVYHDGACöPEVKPVDNFDWSNYHGKWWEVAKYPNSVEKYGKCGWAEYTPE
BBPm 1 DVYHDGACöPEVKPVDNFDWSQYHGKWWEVAKYPNSVEKYGKCGWAEYTPE
FluA 1 DVYHDGACöPEVKPVDNFDWSQYHGKWWEVAKYPSPNGKYGKCGWAEYTPE
DigA16 1 DVYHDGAC^PEVKPVDNFDWSQYHGKWWQVAAYPDHITKYGKCGWAEYTPE
RBP 1 ERDCRVSSFRVKENFDKARFAGTWYAMAKKDPEGLFLQDNIVAEFSVD
BBP 51 ^GK^SVKVSNYHVIHGKEYFIE^GTAYPVGD-SKIGKIYHKL-TY
BBPm 51 ^GK^SVKVSNYHVIHGKEYFIE^GTAYPVGD-SKIGKIYHSL-TY
FluA 51 ^GK^SVKVSRYDVIHGKEYFME^GTAYPVGD-SKIGKIYHSR-TV
DigA16 51 ^GK^SVKVSRYSVIHGKEYFSE^GTAYPVGD-SKIGKIYHSY-TI
RBP 49 ENGHMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASF
BBP 91 GGVTKENVFNVLSTDNKNYIIGYYCK-YDEDKKGHQDFVWVLSR-SKVLTGE
BBPm 91 GGVTKENVFNVLSTDNKNYIIGYYCK-YDEDKKGHQDFVWVLSR-SMVLTGE
FluA 91 GGYTRKTVFNVLSTDNKNYIIGYSCR-YDEDKKGHWDHVWVLSR-SMVLTGE
DigA16 91 GGVTQEGVFNVLSTDNKNYIIGYFCS-YDEDKKGHMDLVWVLSR-SMVLTGE
RBP 98 LQKGNDDHW-IIDTDYETFAVQYSCRLLNLDGTCADSYSFVFARDPSGFSPE
BBP 141 AKTAVENYLIGSPVVDSQKLV-YSDFSEAACKVNN
BBPm 141 AKTAVENYLIGSPVVDSQKLV-YSDFSEAACKVNN
FluA 141 AKTAVENYLIGSPVVDSQKLV-YSDFSEAACKVNN
DigA16 141 AKTAVENYLIGSPVVDSQKLV-YSDFSEAACKVNN
RBP 149 VQKIVRQRQEELCLARQYRLIPHNGYCDGKSERNIL
Shown are the amino acid sequences of lipocalins BBP [29], BBP mutant (BBPm) used as the anticalin scaffold [2], and bovine RBP [13];
and anticalins FluA [2] for binding £uorescein, and DigA16 [3] for binding digoxin. The 16 sites (and corresponding sites in BBP and RBP)
used for generation of the initial phage anticalin libraries are underlined. Other mutations occurring in anticalins selected for ligand binding
are shown in bold.
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CDRs of the two IgG polypeptide chains [17] and lined
mostly by hydrophobic residues: a His, Tyr and Trp from
the light chain (VL variable region), as well as a Trp and
three Tyr residues from the heavy chain (VH). In addition,
probable H-bonds between antibody and hapten are im-
plied by the structure: a His residue (VL 27d, residue
numbering from [18]) with £uorescein oxygen O1, Arg
(VH 34) as well as Ser (VH 91) with £uorescein O3, and
Tyr (VL 32) with £uorescein O4; additional H-bonds ap-
pear to form with bound water molecules [14]. However,
the functional contributions of these H-bonds to the free
energy of £uorescein binding is less clear. For example,
mutational substitution (reviewed in [14]) of Arg (VL 34)
or His (VL 27d) by another basic residue, Lys, led to 10-
fold or 400-fold reductions in binding af¢nity, respectively;
but removal of the basic functionality via Ala substitutions
led to only a 40-fold reduction in af¢nity (ArgCAla) or a
slight improvement in af¢nity (HisCAla). In contrast, sub-
stitutions of hydrophobic residues in the cleft, Trp (VL 96)
or Trp (VH 33) by Tyr caused decreases in binding af¢nity
of about 60- to 100-fold each. Thus, the shape and hydro-
phobic character of the cleft appear most crucial to high
af¢nity ligand binding, though H-bonding interactions may
enhance speci¢city. Indeed, the af¢nities of 4-4-20 for £u-
orescein and rhodamine are 60 pM and s 10 WM, respec-
tively [19], and this has been attributed [14] to the loss of
His and Arg contacts in the aza-substituted rhodamine (see
Figure 1).
A second series of small molecules, steroids, have been
used for the generation of both antibody- and anticalin-
based arti¢cial receptors. The X-ray structures of two
Figure 3. Binding sites for small molecules in antibodies and lipocalins. Ligand structures are shown as connected bonds with heteroatom
coloring (red for oxygen, violet for nitrogen) and the surrounding protein as a solvent-accessible surface (InsightII, MSI San Diego, CA,
USA). (A) The £uorescein:4-4-20 Fab complex (Protein Data Bank ID, 1FLR) illustrates an antibody with a deep binding cleft for
£uorescein. (B) The digoxin:26-10 Fab complex (1IGJ) demonstrates an antibody binding site that only partially buries the digoxin ligand.
(C) The biliverdin IXQ :lipocalin (BBP from the butter£y Pieris brassicae) complex (1BBP) shows a ligand bound by the outer loops of a
lipocalin. A Tyr side chain forms part of a `trap door' across the ligand. (D) The axerophthene:lipocalin (bovine retinol binding protein)
complex (1FEN) exempli¢es a lipocalin binding site that extends into the interior of the L-barrel.
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anti-digoxin antibodies, 26-10 Fab [20] and 40-50 Fab [21]
have been reported. Both have broad speci¢city for bind-
ing related molecules such as ouabain (see Figure 1). The
structure of 26-10 Fab bound to digoxin reveals a shallow
binding site. The ligand carbohydrate groups (see Figure
1), through which conjugation was performed for immuni-
zation, protrude from the antigen binding pocket, in which
the lactone ring is thoroughly surrounded (see Figure 3B).
Interestingly, no H-bonds or salt bridges are seen between
antibody and ligand in this structure, leading to character-
ization of the mechanism of ligand recognition by this anti-
body as shape complementarity [20]. Similarly, hydropho-
bic interactions appear to dominate the interaction of the
other anti-digoxin antibody, 40-50, whose structure has
been reported [21] in complex with ouabain (see Figure
1). Again this binding site is shallow, burying 76% of the
solvent-accessible surface area of the ligand. As these au-
thors suggest, hydrophobic interactions appear to be the
driving force for ligand binding by this KdW0.6 nM af¢nity
antibody. Although H-bonding does occur in this complex,
it has been pointed out that the sites of H-bonding are
conserved in the cardiac glycosides; therefore, these inter-
actions cannot yield speci¢city. In fact, most contact resi-
dues in the complex are aromatics, for example, His (VL
32), His (VH 35), Phe (VH 95), Tyr (VH 100) and Tyr (VH
100c).
Antibody versus anticalin scaffolds
Despite differences in fold and shape, the antibody and
anticalin classes of small molecule binding proteins share
much in common. The monomeric anticalin is similar in
size to a single chain variable domain (VL^VH) of an anti-
body (see Figure 2) which is often used in phage-displayed
libraries (see e.g. [12]). Both form small molecule binding
sites or CDRs by forming binding surfaces from £exible
loops. A technical limitation for the generation of new
binding activities in each case is the need to conjugate
small molecules to carrier proteins for in vitro binding se-
lections (anticalins) or immunizations (antibodies).
Anticalins are distinct in that the binding site for small
molecules may extend into the interior of a well-ordered
L-barrel (see Figure 3). This type of stable secondary struc-
ture may have advantages for certain applications (see be-
low), especially when compared to the £exible loops of
antibody CDRs.
Figure 3 (continued).
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Antibodies are established tools of biochemistry, with dem-
onstrated high af¢nities, often with Kd6 1 nM, and with
remarkable speci¢city. However, the success at generating
anticalins with moderate to high af¢nity for £uorescein and
digitoxigenin, 35 and 2 nM, respectively, with mutations at
only 16^17 sites, suggests that anticalins are a robust scaf-
fold for generating small molecule binding proteins quickly
and ef¢ciently. Antibodies show sequence diversity at
more than 70 positions within the six CDR regions [18].
It is unclear whether, with a small number of side chain
substitutions, £uorescein and digoxin binding sites could
be engineered into the non-cognate anti-digoxin and anti-
£uorescein antibody scaffolds, respectively.
Implications
While molecular recognition has been explored using syn-
thetic non-protein hosts, including combinatorial libraries
(reviewed in [22,23]), this review has focused upon adapt-
ing protein scaffolds to bind small molecules. Several broad
themes emerge from these studies. First, proteins exhibit
remarkable malleability in binding to diverse small mole-
cules. This theme mirrors the observation that diverse
small molecules can bind to the same binding site; for
example, many structurally unrelated small molecules in-
hibit HIV protease by binding with high af¢nity to the
same protease active site (representative examples re-
viewed by [24]). Second, the same small molecule can be
bound tightly and speci¢cally using very different strat-
egies, by structurally unrelated protein scaffolds. This has
also been observed in the diverse protein structures capa-
ble of non-covalent binding to the same small molecule
(e.g. biotin binding by streptavidin and anti-biotin antibod-
ies). Third, based upon the known structures of lipocalin:
small molecule and antibody:small molecule complexes, it
appears that the shape complementarity of the binding
site, as well as hydrophobic interactions, may often be
key to high af¢nity small molecule binding. Together
with a small number of polar interactions, these factors
may also contribute to exquisite speci¢city in ligand rec-
ognition. In this sense, the anticalins, having a preformed
cavity of £uorescein-like or digitoxigenin-like dimensions,
may be easily recruited to bind a diverse range of other
small molecules.
Many practical applications may be envisioned for engi-
neered lipocalins. The reported anticalins are proteins de-
rived from a butter£y protein. Thus, these particular anti-
calins may prove unsuitable for therapeutic applications
due to potential immunogenicity. However, human retinol
binding protein is a member of the lipocalin family and
could presumably be adapted to serve as an arti¢cial re-
ceptor in a manner analogous to the experiments described
here. Small molecule binding activity could be applied to a
number of therapeutic areas, such as the discovery of bind-
ers for cholesterol, leukotrienes, toxic shock inducing cell
wall fragments, and the like.
As binding proteins for speci¢c small molecules, the anti-
calins could ¢nd a host of potential uses from biosensors to
chromatography-based separation technologies. It has been
demonstrated that fusion proteins composed of anticalins
with reporter enzymes such as alkaline phosphatase can be
used for ligand binding assays [3]. In addition, surface
plasmon resonance technology has demonstrated the de-
tection of binding events involving molecules of 6 200
Da mass [25] using immobilized proteins. Engineered anti-
calins could provide a ready source of binding proteins for
rapidly adapting this technology for routine use in quality
control, safety or clinical diagnostics applications. Similarly
immobilized proteins could be used for af¢nity chromatog-
raphy of target compounds.
Conceivably, the anticalin binding site could be modi¢ed
to mimic an enzyme active site to evolve proteins with
catalytic activity. In fact, members of the lipocalin family
can catalyze carotenoid epoxidation in plants [26]. With
their L-barrel architecture, it is reasonable to assume that
anticalins provide a more rigid ligand binding scaffold than
antibodies. Thus, it would be interesting to compare the
catalytic activity of anticalins evolved to bind transition
state analogs with the analogous catalytic antibodies.
More generally, structural studies of newly engineered
anticalins should continue to teach us about the diverse
structural features used by proteins to recognize small mol-
ecule ligands.
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